Church & Dwight delivered a resilient performance in a challenging 2025, with full-year net sales reaching $6.2 billion (up 1.6%) and organic sales growing 0.7% (2% excluding the exited Vitamins and Supplements business). Despite a tough consumer environment and category deceleration to 1.8%, the company successfully mitigated $190 million in tariff exposure down to $25 million and maintained flat gross margins for the year while expanding Q4 margins by 90 basis points. Fourth quarter earnings per share (EPS) rose 12% to $0.86, driven by strong productivity and marketing investments. Looking ahead to 2026, management projects 3-4% organic growth and 5-8% EPS growth, underpinned by a significantly reshaped portfolio that is now 64% premium and only 5% exposed to private label. Key strategic drivers include the expansion of the ARM & HAMMER brand from $2 billion to $3 billion, the launch of TheraBreath toothpaste, and the scaling of the Touchland acquisition.
| Metric | Value | Change |
|---|---|---|
| Full Year Net Sales | $6.2 billion | +1.6% year-over-year |
| Full Year Organic Sales Growth | 0.7% | +2.0% excluding exited VMS business |
| Q4 Earnings Per Share (EPS) | $0.86 | +12% year-over-year |
| Full Year Operating Cash Flow | $1.2 billion | Exceeded outlook, 127% free cash flow conversion |
| Q4 Gross Margin | Not specified | +90 basis points year-over-year |
| Debt-to-EBITDA | 1.5x | Stable despite acquisitions and buybacks |
| Private Label Exposure | 5% | Down from 12% due to portfolio reshaping |
| Digital/E-commerce Sales Penetration | 24% | Up from 2% over the last decade |
Portfolio Reshaping and De-Risking: A major strategic pivot was the exit of the Vitamin/Supplements (VMS) business and other underperforming assets (Spinbrush, Flawless). This reduced private label exposure from 12% to just 5%, significantly de-risking the portfolio. Management emphasized that this shift allows them to reallocate resources toward higher-growth, higher-margin premium brands. This move transforms the company into a more pure-play consumer growth story, removing a persistent drag on margins and management attention.
ARM & HAMMER Expansion ($2B to $3B): Management outlined a clear, multi-pillar strategy to grow their largest brand by 50% over the next few years. This includes 'Good, Better, Best' pricing architecture (already successful in Laundry and Litter), expansion into new categories (fewer, bigger, better), and an in-house licensing incubator model to test new markets before full acquisition. The brand's 'halo effect' across categories allows for efficient marketing spend, supporting this ambitious growth target.
Oral Care and TheraBreath Integration: The company is aggressively expanding into oral care, leveraging the TheraBreath acquisition to target the massive $4.8B toothpaste and $2.4B mouthwash categories. With TheraBreath currently at only 12% household penetration versus 65% for the category, and the launch of a new clinically proven toothpaste, this represents a significant growth vector. Management aims to make TheraBreath the #1 mouthwash and a major player in paste, capitalizing on its superior flavor and clinical efficacy.
International M&A and Scaling: The company is doubling down on international growth, targeting an increase from $1B to $2B in international sales. This will be driven not just by organic expansion of U.S. brands like Hero and TheraBreath (which are already in 50-75 countries), but specifically by international M&A. The acquisition of Graphico in Japan serves as a template for using local platforms to introduce the broader portfolio, indicating a more sophisticated and capital-intensive international strategy.
Digital Transformation and E-Commerce: Digital sales have surged from 2% to 24% of the total business in under a decade. Management is leaning heavily into emerging channels like TikTok Shop and utilizing AI for content creation and media buying. This digital prowess acts as a competitive moat, allowing for rapid testing of new products (like laundry sheets) before broader rollout and providing higher margins through direct-to-consumer channels.
Category Deceleration and Consumer Weakness: Management acknowledged that category growth slowed significantly in 2025 to 1.8% (from 3-4% historically), with consumer sentiment at 5-year lows. While CHD grew share in several categories, a persistently weak macro environment poses a risk to volume growth. The guidance assumes a return to 2% category growth, which may be optimistic if the consumer remains pressured.
Guidance Headwinds and Divestiture Drag: While the 2026 outlook for 3-4% organic growth is healthy, reported sales are guided to be down 1.5% to up 0.5% due to the divestiture of $400M in sales (Vitamins, etc.). This creates a high bar for the remaining business to clear. Additionally, the first half of the year faces specific headwinds including the lapping of inventory destocking and the loss of the OxiClean Costco listing.
Batiste Brand Performance: The BATISTE dry shampoo brand, a key 'Power Brand', struggled in 2025, declining 2.5 share points. While management noted a return to growth in the back half and plans for a 'brand recharge' and innovation (powders, fragrances), the loss of momentum in a previously high-growth beauty adjacent category is a concern requiring close monitoring.
ERP Implementation Risk: Management confirmed an ongoing SAP S4 transformation ('digitizing our core'). While they expressed confidence, ERP transitions carry inherent execution risks regarding supply chain disruption and sales reporting. Management noted they are not expecting a massive sell-in like a competitor, but the transition adds a layer of operational complexity during a year of heavy portfolio change.
Touchland Distribution Risks: There are inherent risks in scaling the Touchland brand without diluting its premium equity. Management emphasized being 'purposeful' and 'picky' about channels (avoiding mass retail for now) to protect the brand's cachet. However, aggressive expansion into club stores (Costco test) and international markets requires careful execution to avoid the 'over-distribution' trap that plagues many high-growth beauty brands.
Overall: Management exhibited a high degree of confidence and enthusiasm, frequently using words like 'ecstatic,' 'momentum,' and 'bright future' to describe the company's position. They were direct and transparent regarding the challenges of 2025, particularly the Vitamin business exit and tariff headwinds, but quickly pivoted to emphasize the strength of the remaining portfolio and the efficacy of their mitigation strategies. The tone shifted from defensive in discussing past headwinds to aggressive and ambitious when outlining future growth initiatives.
Confidence: HIGH - Management provided specific, detailed targets (e.g., ARM & HAMMER $2B to $3B, International $1B to $2B) and demonstrated a track record of meeting financial commitments (beating EPS and cash flow outlooks). Their willingness to set a 100 basis point gross margin expansion target despite inflation signals strong internal conviction.
Management guided to 3% to 4% organic growth for the full year 2026. This is driven by volume growth rather than price, with the U.S. business targeted at 3%, International at 8%, and Specialty Products at 5%. This compares to a 10-year historical average of 4.1%.
Reported sales are expected to be in the range of negative 1.5% to positive 0.5%. This decline relative to organic growth is solely attributed to the exit of approximately $400 million in sales from the Vitamins/Supplements business and other divestitures.
Management expects gross margin improvement of approximately 100 basis points. This is double the typical 'Evergreen' model target of 25-50 bps, driven by portfolio changes (exiting low-margin VMS), productivity gains, and positive mix from acquisitions like Touchland, offsetting ~160 bps of inflation.
EPS is projected to grow 5% to 8% for the year. The growth is expected to be back-half loaded due to higher marketing investments and Touchland SG&A/amortization in the first half.
Operating cash flow is expected to be approximately $1.15 billion, remaining strong and supporting continued capital deployment.
Hedging & Uncertainty: Management used relatively little hedging regarding past performance, speaking definitively about tariff mitigation and share gains ('We grew faster than all of our categories'). However, regarding the future, they employed temporal hedges such as 'over the next few years' and 'aspiration' when discussing the ARM & HAMMER $3B target. They also used probability hedging on the macro environment: 'We're not expecting them [categories] to transform.' This suggests they are confident in their internal execution but cautious about external factors they cannot control.
We grew faster than all of our categories across all 3 divisions. - Richard Dierker, CEO
Our tariff mitigation and response wasn't just industry-leading, I would say it's just leading. - Richard Dierker, CEO
We're down to 5%, right? Vitamins was an extremely large private label business. - Richard Dierker, CEO
We have a 10-year history of 4.1%. - Lee McChesney, CFO
We're laser-focused on mouthwash and toothpaste. - Richard Dierker, CEO
The value of the brand matters in a big way. - Richard Dierker, CEO
We're going to be a value to Tide EVO in a big way. - Richard Dierker, CEO
We have tons of optionality as we move here into '26. - Lee McChesney, CFO
Analyst Sentiment: Analysts were generally inquisitive and focused on the sustainability of the growth trajectory post-portfolio reshaping. Key questions from analysts like Nik Modi (Citi) and Javier Escalante (JPMorgan) probed the strategic logic of the Vitamin exit and the specific mechanics of the ARM & HAMMER expansion. There was skepticism regarding the promotional environment and the ability to maintain margins, with Bonnie Herzog (Wells Fargo) asking about price mix negativity.
Management Responses: Management responses were detailed and direct, often using specific data points to refute concerns (e.g., citing ARM & HAMMER share gains despite promotion levels). They were transparent about the 'mind share' wasted on the Vitamin business, candidly admitting it was a strategic error to hold it as long as they did. They effectively deflected concerns about the ERP transition by contrasting it with a competitor's recent issues.
ARM & HAMMER Growth Strategy: Analysts sought clarity on how the $2B to $3B growth target would be achieved, specifically asking if it was international or domestic. Management clarified it is largely domestic, driven by 'Good, Better, Best' tiering and new category entries.
Vitamin Exit Impact: Questions focused on the cost savings and resource reallocation following the VMS divestiture. Management emphasized that the primary benefit was freeing up management time and focus, rather than just cost savings, calling it a 'strategic pivot point.'
Touchland Brand Equity: Analysts expressed concern about 'over-distributing' Touchland and diluting its premium status. Management reassured investors they would be 'purposeful' with distribution, citing the success of a Costco test and the importance of protecting the brand's 'cache' by sticking to premium channels like Sephora and Ulta.
Guidance Mechanics: Analysts dug into the organic growth guidance, specifically the U.S. vs. International split and the impact of lapping inventory destocking. Management provided the specific split (3% U.S., 8% Int'l) and noted the OxiClean Costco headwind in Q1.
Promotional Environment: Analysts asked about elevated promotions in HPC categories. Management argued that brand value allows them to win share without outspending competitors, citing ARM & HAMMER's value positioning as a competitive advantage in a tight consumer environment.
Church & Dwight (CHD) presents a compelling investment opportunity driven by a strategic portfolio transformation that removes a major drag (Vitamins) and sharpens focus on high-growth, high-margin personal care brands. The company's 'Evergreen' model remains intact, with 2026 guidance of 3-4% organic growth and 5-8% EPS growth demonstrating resilience despite a sluggish macro environment. The de-risking of the portfolio (private label down to 5%) and the reduction of tariff exposure to a negligible amount provide a cleaner earnings profile. Key growth drivers, specifically the expansion of TheraBreath into toothpaste and the international scaling of Hero and Touchland, offer multi-year upside that is not fully priced into the consensus view. The balance sheet remains strong (1.5x leverage), providing ample capacity for M&A, which management is actively pursuing internationally to accelerate growth. While category headwinds and the Batiste turnaround are valid concerns, the company's share gains in core Laundry and Litter categories prove the strength of its value proposition. The shift to a more premium, innovation-led portfolio, combined with operational efficiency (100bps margin expansion guide), supports a re-rating higher. We recommend buying CHD as a defensive growth name with accelerating secular tailwinds from its recent acquisitions.
Management highlighted a persistent deceleration in category growth rates, down to 1.8% in 2025 from a historical 3-4%, and noted consumer sentiment is at '5-year lows.' This indicates a broader trend of consumer weakness and volume pressure in the CPG sector. The shift in consumer preference toward 'value' segments was explicitly noted as a macro tailwind for CHD's ARM & HAMMER brand but a headwind for premium competitors. This suggests a sustained 'trading down' behavior in the household and personal care sectors.
The transcript revealed an intensely promotional environment in HPC categories, with competitors 'price promoting to gain share' as volumes decline. Management noted that 'promotional levels are up' and that the industry is seeing 'negativity on price mix.' This signals a broader risk of margin compression across the household and personal care sectors as brands fight for shelf space and volume in a stagnant market.
The rapid rise of social commerce was highlighted as a major industry shift. Management noted that 'TikTok Shop is actually bigger in the U.S. in terms of GMV ahead of a couple of large beauty retailers already.' This underscores a massive disruption in retail media and discovery, where platforms like TikTok are compressing the journey from inspiration to purchase, forcing CPG companies to rethink their marketing and distribution strategies.